Case Studies: Deployer - Biologics Portfolio

Enabling access to

global biosimilars in Brazil

through strategic partnership

Introduction

A pharmaceutical company based in Brazil sought to expand its biologics portfolio by accessing innovative therapies developed internationally. Focused on enhancing its therapeutic reach with high-quality, differentiated products, the company engaged Trifermed to identify potential assets and facilitate a strategic partnership with a biologics manufacturer.

Through Trifermed’s structured methodology, the client secured a licensing and distribution agreement with a global developer for the commercialization of a biosimilar therapeutic in Brazil.

Background

Brazil's increasing demand for cost-effective and accessible biologics has created new opportunities for therapeutic expansion. The client aimed to strengthen its market offering through partnerships that bring clinically proven biologics to local patients.

The primary objectives were:

  • Identifying a differentiated biosimilar asset with global registration.

  • Securing a strategic partnership.

  • Structuring a deal that enables regulatory approval and local market access in Brazil.

Trifermed supported the end-to-end process, from scouting through to deal execution, ensuring value alignment between both parties.

Services Provided

  • Portfolio Strategy & Asset Identification

  • Partner Identification & Evaluation

  • Deal Structuring & Negotiation Support

Outcomes & Future Development

Thanks to Trifermed’s facilitation, the client signed a strategic licensing and distribution agreement for the Brazilian market. This achievement enabled:

  • Portfolio Expansion: Entry into the competitive biologics segment.

  • Innovation Access: Bringing high-quality international biosimilars to local healthcare systems.

  • Market Execution: A roadmap for regulatory submission and launch in Brazil.